3,490 results on '"Charlotte"'
Search Results
2. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
3. Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of the cell cycle
4. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML
5. NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome
6. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
7. Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey
8. CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma
9. A key role for platelet GPVI in neutrophil recruitment, migration, and NETosis in the early stages of acute lung injury
10. Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study
11. Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma
12. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition
13. IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact
14. Plasma cell–derived mtDAMPs activate the macrophage STING pathway, promoting myeloma progression
15. DOCK11 deficiency in patients with X-linked actinopathy and autoimmunity
16. Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults
17. Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study
18. Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial
19. Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma
20. Immunothrombosis and vascular heterogeneity in cerebral cavernous malformation
21. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
22. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients
23. Gain-of-function mutations in RPA1 cause a syndrome with short telomeres and somatic genetic rescue
24. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+lymphoid malignancies
25. High frequency of clonal hematopoiesis in Erdheim-Chester disease
26. Germline IKAROS dimerization haploinsufficiency causes hematologic cytopenias and malignancies
27. An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial
28. p53 activation during ribosome biogenesis regulates normal erythroid differentiation
29. Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps
30. Common variable immune deficiency: case studies
31. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia
32. Resolvin D4 attenuates the severity of pathological thrombosis in mice
33. Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma
34. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
35. Toward personalized treatment in multiple myeloma based on molecular characteristics
36. Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment
37. Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey
38. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells
39. Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium
40. Activating NSD2 Mutations Drive Oncogenic Reprogramming By Disturbing Epigenetic Landscape in Mantle Cell Lymphoma
41. Interest of Cytoreductive Therapy before Allogenic Hematopoietic Stem Cell Transplantation in Childhood Myelodysplastic Syndromes: A Retrospective Study on Behalf of the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)
42. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease
43. Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma
44. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome
45. Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice
46. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231
47. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission
48. Postinduction molecular MRD identifies patients with NPM1AML who benefit from allogeneic transplant in first remission
49. High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis
50. The effect of variation in donor platelet function on transfusion outcome: a semirandomized controlled trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.